CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America

1st Edition, Volume 37-6 - October 12, 2023
Editors: Caron A Jacobson, Parth S. Shah
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 3 0 0 - 3
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 3 0 1 - 0

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top… Read more

CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL).

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
Preface
The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia
Key points
Introduction and background
Discussion
Summary
Clinics care points
Disclosure
Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
Key points
Introduction
Clinics care points
Disclosure
Funding
Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
Key points
Introduction
Background
Chimeric antigen receptor T-cell therapy in indolent B-non-Hodgkin’s lymphoma
Chimeric antigen receptor T-cell therapy in mantle cell lymphoma
Chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia
Discussion
Chimeric Antigen Receptor T Cells in Multiple Myeloma
Key points
Background
Summary
Conflicts of interest
Disclosure
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
Key points
Introduction
Chimeric antigen receptor-T cells in Hodgkin lymphoma
Chimeric antigen receptor-T cells in T-cell lymphoma
Summary
Clinics care points
Conflict of interest
Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Key points
Introduction
Background
Clinical chimeric antigen receptor T-cell platforms in acute myeloid leukemia
How to reduce on-target toxicity
How to increase efficacy?
Summary
Clinics care points
Disclosure
Funding support
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Key points
Introduction
Patient selection
Challenges to Chimeric Antigen Receptor T-Cells in Solid Tumors
Advancements in Chimeric Antigen Receptor T-Cell Therapy by Tumor Type
Summary
Clinics care points
Disclosures
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells
Key points
Introduction
Early toxicities of chimeric antigen receptor T-cells
Delayed toxicities of chimeric antigen receptor T-cells
Additional considerations and future directions
Summary
Clinics care points
Disclosures
Disclaimer
Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy
Key points
Background
Resistance mechanisms
Summary
Clinics care points
Disclosures
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies
Key points
Introduction
Discussion
Bispecific antibodies in multiple myeloma
Summary
Clinics care points
Disclosure
The Future of Chimeric Antigen Receptor T Cell Therapy
Key points
Introduction
Discussion
Summary
Funding
Conflict of Interest

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Caron A Jacobson

Parth S. Shah